Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 10, 2025

HCC4006

RRID:CVCL_1269
Type: Cell Line

Proper Citation

(RRID:CVCL_1269)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1269

Proper Citation: (RRID:CVCL_1269)

Sex: Male

Defining Citation: PMID:16187286, PMID:20679594, PMID:22460905, PMID:22961666, PMID:23733853, PMID:25485619, PMID:25877200, PMID:26361996, PMID:26589293, PMID:29681454, PMID:30894373, PMID:31068700, PMID:31395879, PMID:39061985

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Protein expression by reverse-phase protein arrays., Omics: Deep proteome analysis., Omics: Deep exome analysis., Omics: Array-based CGH., Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: EGFR genetic alteration cell panel (ATCC TCP-1027)., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Name: HCC4006

Synonyms: HCC-4006, Hamon Cancer Center 4006

Cross References: BTO:BTO_0004081, CLO:CLO_0003657, EFO:EFO_0003132, AddexBio:C0016012/4917, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ATCC:CRL-2871, BioSample:SAMN03471807, BioSample:SAMN03473288, BioSample:SAMN10988526, cancercelllines:CVCL_1269, Cell_Model_Passport:SIDM01596, ChEMBL-Cells:CHEMBL4523544, ChEMBL-Targets:CHEMBL4523575, Cosmic:903602, Cosmic:1028938, Cosmic:1128250, Cosmic:1146936, Cosmic:1802302, Cosmic:2015233, DepMap:ACH-000066,

EGA:EGAS00001000610, EGA:EGAS00001002554, GEO:GSM63351, GEO:GSM108873, GEO:GSM108874, GEO:GSM253408, GEO:GSM434286, GEO:GSM794399, GEO:GSM844552, GEO:GSM887055, GEO:GSM888125, IARC_TP53:30035, IGRhCellID:HCC4006GEO, LiGeA:CCLE_139, PharmacoDB:HCC4006_502_2019, PRIDE:PXD002556, Progenetix:CVCL_1269, PubChem_Cell_line:CVCL_1269, Wikidata:Q54881724

ID: CVCL_1269

Record Creation Time: 20250131T200324+0000

Record Last Update: 20250131T201525+0000

Ratings and Alerts

No rating or validation information has been found for HCC4006.

No alerts have been found for HCC4006.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 135 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Sadeghi M, et al. (2024) Biased signaling by mutant EGFR underlies dependence on PKC? in lung adenocarcinoma. Cell reports, 43(12), 115026.

Ishibashi K, et al. (2024) Astrocyte-induced mGluR1 activates human lung cancer brain metastasis via glutamate-dependent stabilization of EGFR. Developmental cell, 59(5), 579.

Nagoya A, et al. (2023) CKAP4 is a potential exosomal biomarker and therapeutic target for lung cancer. Translational lung cancer research, 12(3), 408.

Qiao Y, et al. (2023) Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection. PloS one, 18(2), e0281281.

Garana BB, et al. (2023) Drug mechanism enrichment analysis improves prioritization of therapeutics for repurposing. BMC bioinformatics, 24(1), 215.

Aldonza MBD, et al. (2023) Multi-targeted therapy resistance via drug-induced secretome fucosylation. eLife, 12.

Letian A, et al. (2023) Proximity proteome mapping reveals PD-L1-dependent pathways disrupted by anti-PD-L1 antibody specifically in EGFR-mutant lung cancer cells. Cell communication and signaling : CCS, 21(1), 58.

Matsubara D, et al. (2023) Genetic and phenotypic determinants of morphologies in 3D cultures and xenografts of lung tumor cell lines. Cancer science, 114(4), 1757.

Sun D, et al. (2023) Multiomics analysis revealed the mechanisms related to the enhancement of proliferation, metastasis and EGFR-TKI resistance in EGFR-mutant LUAD with ARID1A deficiency. Cell communication and signaling : CCS, 21(1), 48.

Bai X, et al. (2023) CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy. Nature communications, 14(1), 1247.

Li J, et al. (2023) FBP1 induced by ?-elemene enhances the sensitivity of gefitinib in lung cancer. Thoracic cancer, 14(4), 371.

Wang Y, et al. (2023) Aberrant m5C hypermethylation mediates intrinsic resistance to gefitinib through NSUN2/YBX1/QSOX1 axis in EGFR-mutant non-small-cell lung cancer. Molecular cancer, 22(1), 81.

Zhang J, et al. (2023) LAFITE Reveals the Complexity of Transcript Isoforms in Subcellular Fractions. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 10(3), e2203480.

de Miguel FJ, et al. (2023) Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer. Cancer cell, 41(8), 1516.

Marrocco I, et al. (2023) L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab. Cell reports. Medicine, 4(8), 101142.

Bao Y, et al. (2023) RBM10 Loss Promotes EGFR-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition. Cancer research, 83(9), 1490.

Xu N, et al. (2023) PUF60 promotes cell cycle and lung cancer progression by regulating alternative splicing of CDC25C. Cell reports, 42(9), 113041.

Guan S, et al. (2022) Metabolic reprogramming by adenosine antagonism and implications in non-small cell lung cancer therapy. Neoplasia (New York, N.Y.), 32, 100824.

Niu N, et al. (2022) ATIC facilitates cell growth and migration by upregulating Myc expression in lung adenocarcinoma. Oncology letters, 23(4), 131.

Sun X, et al. (2022) Modulating environmental signals to reveal mechanisms and vulnerabilities of cancer persisters. Science advances, 8(4), eabi7711.